Statement by ERDC on Tavneos
We know many in our community are hearing news about Tavneos (avacopan) and questions about its safety, specifically regarding liver toxicity. We want to share what we as a patient organization believe and support:
We support patients and their right to informed choice. Every person’s health situation is unique. Decisions about treatment should be made between patients and their healthcare providers based on individual needs and risk tolerance.
Context on Tavneos:
• Liver toxicity (liver injury risk) was included in the original U.S. prescribing label for Tavneos when it was approved in 2021 and has been monitored with regular liver tests during treatment.
• More than 7,000 people have been treated with Tavneos since its approval, and it remains an important therapeutic option for many with ANCA-associated vasculitis.
What this means:
• The risk of liver side effects isn’t new — it was part of the original safety information and is something clinicians monitor regularly.
• Recent regulatory discussions reflect ongoing evaluation of benefit-risk profiles by authorities and manufacturers as part of routine safety oversight.
Our stance:
We are grateful for all available therapies that help manage rare autoimmune diseases — treatments that many years ago didn’t exist. For many, this therapy has made remission, quality of life, and reduced steroid exposure a reality. Each patient must weigh the benefits and risks of any therapy in partnership with their care team.
If you have questions about your treatment:
Please talk with your doctor or healthcare provider — they know your medical history best. Any changes to medications should only be made under professional guidance.
We are here to support you and provide trusted information as new updates emerge. Want to learn more? Read the FAQ released by Amgen.
